Kyle Doherty

2 days ago | onclive.com | Kyle Doherty

The emergence of pirtobrutinib (Jaypirca) has added an additional treatment option for patients with relapsed/refractory chronic lymphocytic leukemia (CLL); however, the growing wealth of choices requires careful consideration of patient needs and disease characteristics in order to select the appropriate therapy, according to Nitin Jain, MD.

3 days ago | targetedonc.com | Kyle Doherty

Ipatasertib plus with fulvestrant (Faslodex) led to significantly longer progression-free survival (PFS) compared with placebo and fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer following disease progression on frontline CDK4/6 inhibitor and aromatase inhibitor (AI) therapy, according to data from the phase 3 FINER trial (NCT04650581) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

3 days ago | onclive.com | Kyle Doherty

China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) seeking the approval of sintilimab (Tyvyt) in combination with fruquintinib (Fruzaqla) for the treatment of patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed treatment with 1 prior TKI.1The NDA is supported by data from the phase 2/3 FRUSICA-2 trial (NCT05522231).

3 days ago | cancernetwork.com | Kyle Doherty

In the phase 2 FDZL-FIX trial (NCT06158919) trial, fruquintinib (Fruzaqla) with chemotherapy and PD-1 inhibition was evaluated as a frontline treatment for patients with HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and showed promising efficacy and an acceptable safety profile, according to results shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

3 days ago | onclive.com | Kyle Doherty

Tivozanib (Fotivda) monotherapy displayed efficacy in patients with metastatic renal cell carcinoma (RCC) who received frontline treatment with ipilimumab (Yervoy) plus nivolumab (Opdivo) or a TKI in combination with an immune checkpoint inhibitor (ICI), according to data from a subgroup analysis of the phase 3 TiNivo-2 trial (NCT04987203) presented during the 2025 ASCO Annual Meeting.1 Patients who received tivozanib monotherapy following first-line TKI plus ICI treatment (n = 41) achieved a...